5-(4-cyclopropylimidazol-1-yl)-N-(5,6-dihydrotetrazolo[1,5-d][1,4]benzoxazepin-8-yl)-2-fluoro-4-methylbenzamide
C23H20FN7O2 — CID 139581321
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-(4-cyclopropylimidazol-1-yl)-N-(5,6-dihydrotetrazolo[1,5-d][1,4]benzoxazepin-8-yl)-2-fluoro-4-methylbenzamide
5-(4-cyclopropylimidazol-1-yl)-N-(5,6-dihydrotetrazolo[1,5-d][1,4]benzoxazepin-8-yl)-2-fluoro-4-methylbenzamide (PubChem CID 139581321) has the molecular formula C23H20FN7O2 and a molecular weight of 445.46 g/mol. Its IUPAC name is 5-(4-cyclopropylimidazol-1-yl)-N-(5,6-dihydrotetrazolo[1,5-d][1,4]benzoxazepin-8-yl)-2-fluoro-4-methylbenzamide.
Molecular Properties
| Compound Name | 5-(4-cyclopropylimidazol-1-yl)-N-(5,6-dihydrotetrazolo[1,5-d][1,4]benzoxazepin-8-yl)-2-fluoro-4-methylbenzamide |
|---|---|
| PubChem CID | 139581321 |
| Molecular Formula | C23H20FN7O2 |
| Molecular Weight | 445.46 g/mol |
| Exact Mass | 445.17 |
| IUPAC Name | 5-(4-cyclopropylimidazol-1-yl)-N-(5,6-dihydrotetrazolo[1,5-d][1,4]benzoxazepin-8-yl)-2-fluoro-4-methylbenzamide |
| SMILES | Cc1cc(F)c(C(=O)Nc2cccc3c2OCCn2nnnc2-3)cc1-n1cnc(C2CC2)c1 |
| InChI | InChI=1S/C23H20FN7O2/c1-13-9-17(24)16(10-20(13)30-11-19(25-12-30)14-5-6-14)23(32)26-18-4-2-3-15-21(18)33-8-7-31-22(15)27-28-29-31/h2-4,9-12,14H,5-8H2,1H3,(H,26,32) |
| InChIKey | YTNHGYBGRLTMDQ-UHFFFAOYSA-N |
| XLogP | 3.50 |
| TPSA | 99.75 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 445.46 |
| LogP ≤ 5 | 3.50 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 139581321 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.